Navigating the Crucial Clinical Trial Design Considerations for CNS Protein Degraders
Time: 9:00 am
day: Conference Day One
Details:
- Outlining experiences of carrying out long-lasting clinical trials for neurodegenerative indications with older patient populations
- Overcoming dosage and toxicology considerations before entering clinical trials
- Discussing the use of biomarkers to monitor brain penetration, target engagement and degradation efficacy
